Celiac Disease May Raise Your Risk of a Deadly Lung Condition, Genetic Study Finds

Celiac disease has long been understood as more than a digestive disorder, but a new line of genetic evidence pushes that understanding in an unexpected direction: toward the lungs. Researchers using a technique called Mendelian randomization have found that celiac disease is associated with a meaningfully higher risk of pulmonary arterial hypertension, a rare but severe condition in which abnormally high pressure in the lung's blood vessels forces the heart to work harder until it eventually fails. The finding is preliminary and needs validation, but the proposed biological chain linking the two conditions is unusually detailed.

Celiac Disease's Causal Link to Pulmonary Arterial Hypertension

Pulmonary arterial hypertension, or PAH, is not ordinary high blood pressure. It affects the small arteries of the lungs specifically, and it often goes undiagnosed for years because early symptoms like shortness of breath and chest pain mimic far more common conditions. That diagnostic delay makes it especially dangerous.

In a Mendelian randomization study published in PubMed, researchers analyzed summary-level genome-wide association study data from the FinnGen consortium to test whether the genetic predisposition to celiac disease was associated with higher PAH risk. The logic of Mendelian randomization is that genetic variants, unlike lifestyle factors, are assigned at birth and cannot be caused by a later disease, so they offer a more reliable way to test causal direction than conventional observational studies.

In the discovery cohort, the univariable analysis produced an odds ratio of 1.148 (95% CI, 1.027 to 1.282; P = .015), suggesting roughly a 15% higher odds of PAH among those genetically predisposed to celiac disease. A meta-analysis combining two cohorts tightened the estimate: OR 1.136 (95% CI, 1.065 to 1.212; P less than .001). Crucially, the association held up after adjusting for obesity and smoking in a multivariable analysis, which rules out two obvious confounders.

Why the Gut-Lung Axis Makes Biological Sense

The mechanism the researchers propose runs through the gut. In active celiac disease, the immune response to gluten damages the intestinal lining, impairing tight-junction proteins including zonulin. That impairment allows gluten peptides and microbial antigens, including lipopolysaccharides from Gram-negative bacteria, to enter the bloodstream. Once circulating, these bacterial products can trigger pulmonary perivascular inflammation, the kind of persistent irritation around lung blood vessels that drives the vascular remodeling seen in PAH.

The microbiome shift in celiac disease compounds this. Patients tend to show lower levels of beneficial species such as Lactobacillus and Bifidobacterium and higher levels of potentially pathogenic ones like Bacteroides and E. coli. PAH patients show a similar dysbiosis, and gut microbial metabolite changes, specifically decreased short-chain fatty acids and increased trimethylamine N-oxide (TMAO), are thought to promote inflammation and vascular stiffening in the lungs. Research on the gut-to-cardiovascular inflammatory axis in celiac disease has shown that vascular dysfunction in active celiac disease can involve precisely this kind of gut-derived oxidative stress, and that a gluten-free diet may begin to reverse it.

Beyond the gut barrier, increased lung permeability has also been observed in celiac patients, hinting at a generalized defect in mucosal barriers that extends beyond the intestine.

Systemic Lupus as an Unexpected Mediator

One of the more striking results from the mediation analysis is how much of the celiac-PAH pathway appears to run through a third autoimmune disease: systemic lupus erythematosus (SLE). In the analysis, SLE accounted for 30.4% of the mediation (95% CI: 3.6% to 57.2%; P = .032). That is a substantial share, and it points to a broader pattern of immune dysregulation rather than a simple gut-to-lung story.

Celiac disease and SLE share HLA haplotypes and immune pathways, and PAH is a recognized complication of SLE. The implication is that some celiac patients may develop subclinical lupus-like immune activity that independently drives pulmonary vascular disease. How often this actually happens in the celiac population, and whether it is detectable before PAH symptoms appear, is not yet known.

Open Questions About Microbiome Causality and Study Scope

The researchers are explicit about what this study cannot yet answer. The GWAS data comes from primarily European populations via FinnGen, so generalizability to other ancestries is uncertain. More importantly, Mendelian randomization estimates genetic predisposition, not the actual presence of active celiac disease, so the analysis cannot distinguish between well-controlled celiac patients on a gluten-free diet and those with ongoing intestinal damage.

That gap matters because evidence on whether a gluten-free diet reduces cardiovascular risk in celiac patients remains unclear, and the same ambiguity applies here. If the gut barrier is the primary driver of PAH risk, then strict dietary adherence might attenuate that risk over time, but no data currently supports that inference. The researchers also flag that neither PAH patient cohorts nor animal models have yet been used to validate the microbiome-mediation hypothesis, and that the specific role of the airway and lung microbiome in infection-associated PAH remains uninvestigated.

What Clinicians and Celiac Patients Should Watch For

For now, this research sits firmly in the emerging category: the genetic signal is real and statistically robust, but the biological pathway is still largely inferred from mechanistic plausibility rather than direct experimental evidence. Validation in larger, more diverse PAH cohorts and in animal models is the obvious next step, as is research into whether microbiome restoration, through probiotics, dietary intervention, or fecal transplant, can blunt the pulmonary effects.

For clinicians managing celiac patients, the practical message is modest but worth noting. PAH is rare enough that population-level screening is not warranted on the basis of this single study. But in celiac patients who develop unexplained breathlessness or exercise intolerance, adding PAH to the differential a little earlier than usual may be reasonable. The genetic evidence suggests the gut and the lung are more tightly linked in autoimmune disease than standard organ-by-organ care models tend to assume.

Evidence rating

EMERGING — 86/100

Caveats:

• Mendelian randomization establishes genetic-level causal inference but cannot fully replicate the complexity of real-world disease progression — confounding by pleiotropy remains possible.
• The gut microbiome mechanisms (dysbiosis, LPS translocation, SCFA/TMAO shifts) are proposed pathways supported by prior literature but were not directly measured in this study.
• Funding source was not disclosed, so independent verification of this study's conclusions is advisable.
• The PAH outcome is rare, and GWAS-based estimates may not translate directly to individual clinical risk — replication in clinical cohorts is needed.

Two-sample Mendelian randomization study using large-scale GWAS data from the FinnGen consortium, with meta-analysis across two independent cohorts. The design supports causal inference at the genetic level but cannot directly confirm the proposed biological mechanisms — including gut dysbiosis, barrier permeability, and metabolite shifts — which are drawn from prior literature rather than measured in this study. Not yet replicated in prospective clinical cohorts or validated in animal models.

References

1. (2026). Could Celiac Disease Raise the Risk of Pulmonary Arterial Hypertension?. https://www.celiac.com/celiac-disease/could-celiac-disease-raise-the-risk-of-pulmonary-arterial-hypertension-r7236/
2. About Pulmonary Hypertension | Heart Disease – CDC. cdc.gov. https://www.cdc.gov/heart-disease/pulmonary-hypertension/index.html
3. Meng Wu, Weidong Song, Xin Guo, Zhongyuan Lu, Jin Yang, Zhimei Hu (2026). Celiac disease increases the risk of pulmonary arterial hypertension: A multivariable Mendelian randomization and mediation analysis. Medicine. https://doi.org/10.1097/md.0000000000048334
4. Karin Keppeler, Aline Pesi, Simon Lange, et al. (2024). Vascular dysfunction and arterial hypertension in experimental celiac disease are mediated by gut-derived inflammation and oxidative stress. Redox Biology. https://doi.org/10.1016/j.redox.2024.103071
5. Celiac Disease and the Risk of Cardiovascular Diseases – PMC – NIH. NIH. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8909873/